Cancer Stem Cell News Volume 12.12 | Mar 28 2023

    0
    273








    2023-03-28 | CSCN 12.12


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.12 – 28 March, 2023
    TOP STORY

    Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor-Initiating Stem-Like Cells

    Investigators identified circulating tumor cell biomarkers and effective combinations of tumor-initiating stem-like cell-specific, repurposed FDA-approved drugs.
    [Advanced Science]

    Full Article
    PUBLICATIONSRanked by the impact factor of the journal

    Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells

    Researchers reported that terminally exhausted (TTEX) cells actively participated in tumor progression by modulating CSCs. TTEX cells strongly correlated with elevated CSC frequency in poorly immune-infiltrated advanced human breast and ovarian carcinomas.
    [Cancer Research]

    Abstract

    Tumor Microenvironment-Responsive Nanoherb Delivery System for Synergistically Inhibition of Cancer Stem Cells

    Monodisperse hollow-structured MnO2 was successively modified with hyaluronic acid to enhance targeting CSCs with high CD44 expression levels.
    [ACS Applied Materials & Interfaces]

    AbstractGraphical Abstract

    A Novel Lonidamine Derivative Targeting Mitochondria to Eliminate Cancer Stem Cells by Blocking Glutamine Metabolism

    Investigators reported a novel derivative of lonidamine, namely HYL001, which selectively and potently inhibited CSCs by targeting mitochondria.
    [Pharmacological Research]

    Full ArticleGraphical Abstract

    Development of DNA Aptamers for Visualization of Glial Brain Tumors and Detection of Circulating Tumor Cells

    Scientists presented DNA aptamers capable of specific binding to glial tumor cells in vitro, ex vivo, and in vivo for visualization diagnostics of central nervous system tumors.
    [Molecular Therapy – Nucleic Acids]

    AbstractGraphical Abstract

    Discovery of YH677 as a Cancer Stemness Inhibitor That Suppresses Triple-Negative Breast Cancer Growth and Metastasis by Regulating the TGFβ Signaling Pathway

    Harmine was identified as a hit compound based on phenotypic screening of a 2D assay and patient-derived organoid model that was established from a patient with multiple drug resistance and breast metastases.
    [Cancer Letters]

    Abstract

    Matrix Gla Protein Drives Stemness and Tumor Initiation in Ovarian Cancer

    Researchers investigated the molecular and funcitonal makeup of ovarian CSCs (OCSCs) in clinically relevant model systems, and revealed that Matrix Gla Protein was markedly enriched in OCSCs.
    [Cell Death & Disease]

    Full Article

    G9a Promotes Immune Suppression by Targeting the Fbxw7/Notch Pathway in Glioma Stem Cells

    The authors investigated the effects of histone methyltransferases 2, EHMT2 or G9a, on immunosuppressive tumor microenvironment and whether this effect was related to changes on cell stemness.
    [CNS Neuroscience & Therapeutics]

    Full Article

    TIPE2 Sensitizes Breast Cancer Cells to Paclitaxel by Suppressing Drug-Induced Autophagy and Cancer Stem Cell Properties

    The in vitro and in vivo study demonstrated that tumor necrosis factor-α-induced protein-8-like-2 (TIPE2) sensitized breast cancer cells to paclitaxel by suppressing drug-induced autophagy and CSC properties.
    [Human Cell]

    Abstract
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    REVIEWS

    Eradicating the Tumor “Seeds”: Nanomedicines-Based Therapies against Cancer Stem Cells

    The authors summarize the biological hallmarks and markers of CSCs, and the nanotechnology-based therapies to eradicate them.
    [Daru-Journal Of Pharmaceutical Sciences]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    FDA Floats Oncology Authorization Shake-Up, Pitching ‘One-Trial’ Model for Accelerated and Full Approval

    The FDA outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval.
    [Fierce Biotech]

    Press Release
    FEATURED EVENT

    Integrative Molecular Epidemiology Workshop: Bridging Cancer Biology and Precision Medicine

    July 24 – 28, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Staff Scientist – Molecular and Cellular Mechanisms of Breast Cancer Initiation

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Fellow – Tumor Suppressor p53

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Associate Research Scientists – Cancer Genetics

    Columbia University – New York City, New York, United States

    Postdoctoral Associate – Cancer Stem Cell Biology

    Baylor College of Medicine – Houston, Texas, United States

    Staff Scientist – Pediatric Brain Tumors

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter